Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Shanghai Pharmaceuticals Holding Co., Ltd clinical trials
Also known as SPH.
Part of Shanghai Shangshi (Group) Co., Ltd., which holds 38.76% as of 2025-12-31. Source
The registry lists 40 studies whose lead sponsor is Shanghai Pharmaceuticals Holding Co., Ltd or one of 1 company grouped under it. 14 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 19, 2026.
Keep track of what changes. Save the Shanghai Pharmaceuticals Holding Co., Ltd studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesWhere
- China
- 40
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Shanghai Pharmaceuticals Holding Co., Ltd.
- Shanghai Pharmaceuticals Holding Co., Ltd35 studiesSame company
Something wrong?
- Techpool Bio-Pharma Co., Ltd.5 studies →Acquired — became part of Shanghai Pharmaceuticals Holding Co., Ltd, Aug 21, 2018 · source ↗
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 40 of 40.
- A Phase II Clinical Study of LT3001 for Injection in the Treatment of Acute Ischemic StrokeNot yet recruitingNCT07754825Phase 2
- A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.RecruitingNCT05944224Phase 1/2
- A Clinical Study of T3011 in Subjects With Advanced MelanomaRecruitingNCT06214156Phase 1/2
- A Clinical Study of SPH7854 Granules in Healthy Subjects.RecruitingNCT06483373Early Phase 1
- SPH5030 Tablets in Subjects With Advanced Her2-positive Solid TumorsRecruitingNCT05245058Early Phase 1
- A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid TumorsRecruitingNCT06214143Phase 1/2
- Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.RecruitingNCT05872347Phase 2
- Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)RecruitingNCT05145361Early Phase 1
- A Clinical Study of SPH9788 Tablets in Healthy Chinese Subjects.RecruitingNCT06839131Phase 1
- Efficacy and Safety of LT3001 on Treating the Acute Ischemic StrokeRecruitingNCT05686642Phase 2
- Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast CancerRecruitingNCT05860465Phase 2/3
- A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors.RecruitingNCT06487455Phase 1
- Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast CancerRecruitingNCT05744687Phase 2/3
- A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.RecruitingNCT06434597Phase 2
- A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's SarcomaCompletedNCT05046314Phase 2
- A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative ColitisCompletedNCT05770609Phase 2
- Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney DiseaseCompletedNCT05593575Phase 2
- Clinical Study of SPH3348 Tablets, a C-Met Inhibitor, in Patients with Advanced Solid TumorsCompletedNCT05088070Phase 1
- Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid TumorsCompletedNCT05905614Phase 1/2
- Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential HypertensionCompletedNCT05359068Phase 3
- A Food Effect Study of SPH5030 Tablets.CompletedNCT06372223Phase 1
- A Clinical Study of SPH6516 Tablets in the Treatment of Advanced Solid Tumors.CompletedNCT06266923Early Phase 1
- B003 in Patients With HER2-positive Recurrent or Metastatic Breast CancerCompletedNCT03953833Phase 1
- Safety and Efficacy of T8 on Treating Chronic Abnormal Immune Activation in HIV/AIDS PatientsCompletedNCT04084444Phase 2
- B002 in Patients With HER2-positive Breast CancerCompletedNCT04382352Phase 1
- Study on Human Mass Balance of SPH3127 TabletsCompletedNCT05593562Phase 1/2
- Single Ascending Dose Study of Safety and Tolerability of SPH3127 Tablet in Chinese Healthy VolunteersCompletedNCT03128138Phase 1
- Drug-drug Interaction Study of SPH3127CompletedNCT05359055Phase 1/2
- Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension PatientsCompletedNCT03756103Phase 2
- B001 in Patients With CD20 Positive B-cell Non Hodgkin's LymphomaCompletedNCT03332121Phase 1
- The Tolerability and Pharmacokinetics of Multiple Doses of SPH3127 in Chinese Healthy PeopleCompletedNCT03255993Phase 1
- The Effect of Food Intake on the Pharmacokinetic of Single Dose SPH3127 Tablets in Chinese Health SubjectsCompletedNCT03249753Phase 1
- Phase I Study of SPH1188-11 in NSCLCWithdrawnNCT03231475Phase 1
- Post-market Safety Reassessment of Ulinastatin for InjectionStatus unknownNCT02520570
Sponsor listed in the registry: Techpool Bio-Pharma Co., Ltd. · First submitted before Techpool Bio-Pharma Co., Ltd. became part of Shanghai Pharmaceuticals Holding Co., Ltd
- The Safety and Dose Response Relationship of Ulinastatin for Acute Respiratory Distress Syndrome(ARDS)Status unknownNCT02895191Phase 2
Sponsor listed in the registry: Techpool Bio-Pharma Co., Ltd. · First submitted before Techpool Bio-Pharma Co., Ltd. became part of Shanghai Pharmaceuticals Holding Co., Ltd
- Ulinastatin in Severe Acute PancreatitisSuspendedNCT01132521Phase 4
Sponsor listed in the registry: Techpool Bio-Pharma Co., Ltd. · First submitted before Techpool Bio-Pharma Co., Ltd. became part of Shanghai Pharmaceuticals Holding Co., Ltd
- Ulinastatin Injection in in Pediatric Patients Undergoing Open Heart SurgeryStatus unknownNCT02527811Phase 4
Sponsor listed in the registry: Techpool Bio-Pharma Co., Ltd. · First submitted before Techpool Bio-Pharma Co., Ltd. became part of Shanghai Pharmaceuticals Holding Co., Ltd
- The Study to Reevaluate the Safety and Efficacy of Human Urinary KallikreinStatus unknownNCT02562183Phase 4
Sponsor listed in the registry: Techpool Bio-Pharma Co., Ltd. · First submitted before Techpool Bio-Pharma Co., Ltd. became part of Shanghai Pharmaceuticals Holding Co., Ltd
- Hydroxytriptolide in Active Rheumatoid Arthritis Patients With an Inadequate Response to MethotrexateCompletedNCT02202395Phase 1/2
- Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing SpondylitisCompletedNCT02201043Phase 2